Aducanumab and adenoviral COVID-19 vaccines: increased cerebral hemorrhage risk?

MohanaSundaram, ArunSundar; Thukani Sathanantham, Shanmugarajan; Sveikata, Lukas; Lalla, Rakesh Shyam; Sveikatienė, Renata; Kaushik, Ajeet; Velayutham, Ravichandiran

doi:10.1080/14737175.2022.2053112

Scientific article

Editorial

English

Aducanumab and adenoviral COVID-19 vaccines: increased cerebral hemorrhage risk?

ContributorsMohanaSundaram, ArunSundar

; Thukani Sathanantham, Shanmugarajan; Sveikata, Lukas

; Lalla, Rakesh Shyam; Sveikatienė, Renata; Kaushik, Ajeet; Velayutham, Ravichandiran

Published inExpert review of neurotherapeutics, vol. 22, no. 4, p. 283-286

Publication date2022-04

First online date2022-03-28

Keywords

Aducanumab
Alzheimer’s disease
COVID-19 vaccines
Amyloid-related imaging abnormalities
Cerebral hemorrhage
Alzheimer Disease
Amyloid beta-Peptides
Antibodies, Monoclonal, Humanized / adverse effects
COVID-19
COVID-19 Vaccines / adverse effects
Cerebral Hemorrhage / chemically induced
Humans

Affiliation entities

Not a UNIGE publication

Research groups

Neuropsychologie et neurologie comportementale (951)

Funding

Swiss National Science Foundation - The impact of blood pressure profile and variability on the course of pre-clinical Cerebral Amyloid Angiopathy: risk of intracerebral hemorrhage and cognitive decline [191584]

Citation (ISO format)

MOHANASUNDARAM, ArunSundar et al. Aducanumab and adenoviral COVID-19 vaccines: increased cerebral hemorrhage risk? In: Expert review of neurotherapeutics, 2022, vol. 22, n° 4, p. 283–286. doi: 10.1080/14737175.2022.2053112

Article (Published version)

Identifiers

PID : unige:171848
DOI : 10.1080/14737175.2022.2053112
PMID : 35275787

Additional URL for this publicationhttps://www.tandfonline.com/doi/full/10.1080/14737175.2022.2053112

Journal ISSN1473-7175

51views

1downloads

Creation28/04/2023 12:26:45

First validation02/10/2023 14:51:14

Update time02/10/2023 14:51:14

Status update02/10/2023 14:51:14

Last indexation01/11/2024 06:13:11

Archive ouverte UNIGE

Aducanumab and adenoviral COVID-19 vaccines: increased cerebral hemorrhage risk?

Technical informations